Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease

Neuroscience

Volumn 102, Issue 4, 2001, Pages 899-904

  Ross, B M ^a,c   Mamalias, N ^a   Moszczynska, A ^a   Rajput, A H ^b   Kish, S J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

CDP choline; Cytidylyltransferase; Membrane; Oxidative stress; Phospholipase

Indexed keywords

BRAIN ENZYME; CHOLINE KINASE; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; CHOLINEPHOSPHOTRANSFERASE; ETHANOLAMINE KINASE; ETHANOLAMINE PHOSPHATE CYTIDYLYLTRANSFERASE; GLYCEROPHOSPHOCHOLINE PHOSPHODIESTERASE; LYSOPHOSPHOLIPASE; LYSOPHOSPHOLIPID; MEMBRANE PHOSPHOLIPID; PHOSPHATIDYLSERINE SYNTHASE; PHOSPHOLIPASE A; UNCLASSIFIED DRUG;

AGED; ARTICLE; AUTOPSY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE DEGENERATION; NERVE REGENERATION; PARKINSON DISEASE; PHOSPHOLIPID MEMBRANE; PHOSPHOLIPID METABOLISM; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; CELL MEMBRANE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; CYTIDINE DIPHOSPHATE CHOLINE; ENZYME ACTIVATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHOLIPASES A; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; SUBSTANTIA NIGRA;

EID: 0035857445     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00501-7     Document Type: Article

References (37)

1. Lipid peroxidation inhibits oleoyl-CoA: 1-acyl-sn-glycero-3-phosphocholine O-acyltransferase in rat CNS axolemma-enriched fractions
2. Lipid peroxidation inhibits acyl-CoA:-1-acyl-sn-glycero-3-phosphocholine O-acyltransferase but not CTP: Phosphocholine cytidylyltransferase activity in rat brain membranes
3. Susceptibility of rat retina acyl-CoA:1-acyl-sn-glycero-3-phosphocholine O-acyltransferase and CTP: Phosphocholine cytidylyltransferase activity to lipid peroxidation and hydroperoxide treatment
4. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease
5. General and dramatic glial reactions in Alzheimer brains
6. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: An HPLC and ESR study
7. Citicoline in the treatment of Parkinsons's disease
8. Neuropathology of Parkinson's disease
9. Fatty acid incorporation depicts brain activity in a rat model of Parkinson's disease
10. A kinetic mechanism for modulation of the activity of microsomal UDP-glucorynyltransferase by phospholipids. Effect of lysophosphatidylcholines
11. Dopamine-1 receptor G-protein coupling and the involvement of phospholipase A2 in dopamine-1 receptor mediated cellular signaling mechanisms in the proximal tubules of SHR
12. Oxidative mechanisms in nigral cell death in Parkinson's disease
13. Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls
14. Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type I
15. Deficiency of vitamin E and selenium enhances calcium-independent phospholipase A2 activity in rat lung and liver
16. The neuropathology of "typical" Friedreich's ataxia in Quebec
17. Citicoline in the treatment of Parkinson's disease
18. New insights on mammalian phospholipase A2(s); comparison of arachidonyl-selective and -nonselective enzymes
19. Characterization of a chimeric D3/D2 dopamine receptor expressed in CHO cells
20. Role of lipid structure in the activation of phospholipase A2 by peroxidised phospholipids
21. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigrostriatum of Parkinson's disease brain
22. Srtuctural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype
23. Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich's ataxia and spinocerebellar atrophy type-1
24. Characterisation of a novel phospholipase A2 activity in human brain
25. Characterisation of lysophospholipid metabolising enzymes in human brain
26. Phospholipid biosynthetic enzymes in human brain
27. Phospholipid metabolising enzymes in Alzheimer's disease: Increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity
28. Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: Possible implications for Parkinson's disease
29. Phospholipase A2 activity is selectively decreased in the striatum of chronic cocaine users
30. Multiple forms of the enzyme glycerophosphodiesterase are present in human brain
31. A selective increase in particulate superoxide disomutase activity in Parkinson's disease
32. Activation of phospholipase A2 in 1-palmitoyl-2-oleoyl-sn-3 phosphocholine liposomes containing lipid ozonation products
33. Oxidative stress in Parkinson's disease
34. Glutathione-related enzymes in brain in Parkinson's disease
35. Inhibition of microsomal lipid peroxidation by glutathione and glutathione transferases B and A. Role of endogenous phospholipase A2
36. A new role for phospholipase A2: Protection of membranes from lipid peroxidation damage
37. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2